 |
 |
 |
|
|
Nursing Pharmacology Chapter 33-34: Anticancer Drugs
|
|
|
|
|
|
|
Hormonal Anticancer Drugs:
Androgen receptor "superantagonist"3
Overview: Enzalutamide (Xtandi)
|
Mechanism of Action:
Enzalutamide (Xtandi)
is considered a "superantagonist" because of its pure androgen receptor
"signaling" inhibitor characteristics.5
Enzalutamide has not been shown to exhibit agonist characteristics.
Enzalutamide androgen receptor inhibition includes:5
Inhibition of androgen receptor nuclear translocation
Inhibition of DNA binding
Inhibition of coactivator mobilization
Enzalutamide
administration promotes:
Apoptosis
Decreased prostate tumor volume.
Enzalutamide (Xtandi) is a recently approved second-generation
antiandrogen agent.
Initially approved in 2018 for castration-resistant prostate cancer treatment, Enzalutamide (Xtandi) was subsequently approved by the FDA for castration-sensitive prostate cancer in 2019.
Enzalutamide joins apalutamide (Erleada) in the second-generation nonsteroidal antiandrogen category1.
Enzalutamide, and antagonist acting at the androgen receptor, is a diarylthiohydantoin agent that binds to the androgen receptor within affinity notably greater that that observed with bicalutamide or flutamide.3
In addition to acting at the receptor:3
Enzalutamide interferes with nuclear translocation of androgen receptor
Impairs DNA-binding to androgen response elements
Inhibits coactivator recruitment.3
Absorption, Distribution, Biotransformation, Excretion:13
Enzalutamide is administered by the oral route of administration and can be taken with or without food.
This drug is substantially bound to plasma proteins (about 98%), mainly to serum albumin.
Biotransformation: Its active metabolite, N-desmethyl enzalutamide is also substantially bound (95%) to plasma proteins.
Enzalutamide is metabolized by the cytochrome P450 isoform CYP2C8 to an active metabolite N-desmethyl enzalutamide as well as by the isoform CYP3A4.
Elimination is mainly by liver metabolism.
The enzalutamide half-life (t1/2) is about 6 days.
The mean N-desmethyl enzalutamide terminal t1/2 is about 8 days.
Clinical Uses:
|
Adverse Effects:
Common adverse reactions (>10%) (partial list) include:
Cardiovascular effects such as:
Peripheral edema
Hypertension
CNS effects including:
Fatigue
Dzziness
Headache
Endocrine and metabolic abnormalities such as:
Hyperglycemia
Gastrointestinal effects such as
Constipation
Diarrhea
Nausea
Appetite reduction.
Hematological effects including
Reduced neutrophils and
Decreased white blood cell count.
Respiratory and neuromuscular/skeletal effects also occur.
|
|
|
|
|
|
|
|
|
This Web-based pharmacology teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information. Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals. |
